Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) — The global regenerative medicine market, valued at US$13.5 billion in 2022, stood at US$16.0 billion in 2023 and is projected to advance at a resilient CAGR of 25.1% from 2023 to 2028, culminating in a forecasted valuation of US$49.0 billion by the end of the period. This acceleration is driven by the surging demand for personalized medicine, expanding applications in new therapeutic areas, and a wave of regulatory approvals and strategic alliances among leading market players.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579
What’s Driving This Market Surge?
The regenerative medicine sector is witnessing unprecedented momentum as healthcare providers and biopharmaceutical innovators pivot towards tailored, patient-specific solutions. Increasing collaborations between major pharmaceutical companies, biotechnology firms, and research institutions are unlocking opportunities in oncology, neurology, musculoskeletal disorders, and beyond. With approvals for advanced cell and gene therapies on the rise, the market is positioned for sustained and transformative expansion.
Where Is Growth Concentrated?
- Product Leadership: The cell therapy segment led the market in 2022, fueled by the adoption of stem cell therapy and expanding use of hematopoietic stem cell transplantation (HSCT).
- Therapeutic Dominance: Musculoskeletal disorders emerged as the largest therapeutic area, reflecting the growing prevalence of orthopedic conditions and advancements in musculoskeletal regeneration research.
- Regional Momentum: North …